Upgrade to SI Premium - Free Trial

Palvella Therapeutics (PVLA)

108.67 -6.15 (5.36%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/14/26 *Est.)

Latest Headlines

Palvella Therapeutics completes FDA pre-NDA meeting for QTORIN rapamycin June 3, 2026 7:30 AM - StreetInsider Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations June 3, 2026 7:30 AM - Globe NewsWire Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 2, 2026 7:30 AM - Globe NewsWire Palvella Therapeutics receives Yale-licensed patent for QTORIN pitavastatin May 27, 2026 7:31 AM - StreetInsider Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 May 27, 2026 7:30 AM - Globe NewsWire Form 4 PALVELLA THERAPEUTICS, For: May 20 Filed by: Goin Kathleen May 22, 2026 4:06 PM - SEC Filing Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards May 21, 2026 7:30 AM - Globe NewsWire Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen May 20, 2026 5:48 PM - SEC Filing Form 8-K PALVELLA THERAPEUTICS, For: May 20 May 20, 2026 4:35 PM - SEC Filing Palvella presents positive data for QTORIN rapamycin at vascular congress May 20, 2026 4:30 PM - StreetInsider Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise May 20, 2026 4:30 PM - Globe NewsWire Form 8-K PALVELLA THERAPEUTICS, For: May 15 May 15, 2026 7:30 AM - SEC Filing Palvella reports positive bleeding results from rapamycin trial May 15, 2026 7:30 AM - StreetInsider Palvella reports positive bleeding results from QTORIN rapamycin trial May 15, 2026 7:30 AM - StreetInsider Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Der May 15, 2026 7:30 AM - Globe NewsWire Palvella Therapeutics moves to NASDAQ Global Market May 13, 2026 7:30 AM - StreetInsider Form 8-K PALVELLA THERAPEUTICS, For: May 11 May 13, 2026 7:30 AM - SEC Filing Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market May 13, 2026 7:30 AM - Globe NewsWire Stephens Starts Palvella Therapeutics (PVLA) at Overweight May 12, 2026 2:54 AM - StreetInsider Palvella Therapeutics (PVLA) PT Lowered to $240 at Mizuho May 11, 2026 6:43 AM - StreetInsider Form 8-K PALVELLA THERAPEUTICS, For: May 07 May 7, 2026 9:10 AM - SEC Filing Form 10-Q PALVELLA THERAPEUTICS, For: Mar 31 May 7, 2026 8:31 AM - SEC Filing Palvella Therapeutics (PVLA) Misses Q1 EPS by 120c May 7, 2026 8:10 AM - StreetInsider Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 7, 2026 7:30 AM - Globe NewsWire Oppenheimer Assumes Palvella Therapeutics (PVLA) at Outperform May 4, 2026 8:16 AM - StreetInsider Palvella Therapeutics begins Phase 2 trial for rare skin condition May 4, 2026 7:30 AM - StreetInsider Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas May 4, 2026 7:30 AM - Globe NewsWire Form ARS PALVELLA THERAPEUTICS, For: Dec 31 April 30, 2026 4:20 PM - SEC Filing Form DEFA14A PALVELLA THERAPEUTICS, April 30, 2026 4:18 PM - SEC Filing Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 April 30, 2026 4:09 PM - SEC Filing Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 April 30, 2026 7:30 AM - Globe NewsWire Palvella to present QTORIN rapamycin study results at vascular congress April 20, 2026 7:30 AM - StreetInsider Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 April 20, 2026 7:30 AM - Globe NewsWire Form 4 PALVELLA THERAPEUTICS, For: Apr 15 Filed by: Goin Kathleen April 17, 2026 4:05 PM - SEC Filing Form 4 PALVELLA THERAPEUTICS, For: Apr 13 Filed by: Doux John April 15, 2026 4:06 PM - SEC Filing Form 3 PALVELLA THERAPEUTICS, For: Apr 13 Filed by: Doux John April 15, 2026 4:05 PM - SEC Filing Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen April 15, 2026 4:00 PM - SEC Filing Palvella appoints dermatologist John Doux to board of directors April 13, 2026 7:30 AM - StreetInsider Form 8-K PALVELLA THERAPEUTICS, For: Apr 13 April 13, 2026 7:30 AM - SEC Filing Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors April 13, 2026 7:30 AM - Globe NewsWire Form 8-K PALVELLA THERAPEUTICS, For: Apr 07 April 7, 2026 12:45 PM - SEC Filing Palvella Therapeutics names Kent Taylor sales chief April 7, 2026 12:26 PM - StreetInsider Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales April 7, 2026 12:26 PM - Globe NewsWire Form 4 PALVELLA THERAPEUTICS, For: Mar 30 Filed by: JENKINS GEORGE M April 1, 2026 4:06 PM - SEC Filing Mizuho on Palvella Therapeutics (PVLA): remain bullish given QTORIN potential April 1, 2026 10:04 AM - StreetInsider Palvella Therapeutics (PVLA) PT Raised to $240 at Chardan March 31, 2026 4:41 PM - StreetInsider Stifel stays Buy on Palvella: multiple 'pipeline-in-a-product' opportunities March 31, 2026 3:06 PM - StreetInsider Palvella Therapeutics (PVLA) PT Raised to $210 at Oppenheimer, 'Shares Again Become Highly Attractive' March 31, 2026 2:39 PM - StreetInsider Form 10-K PALVELLA THERAPEUTICS, For: Dec 31 March 31, 2026 8:31 AM - SEC Filing Form 8-K PALVELLA THERAPEUTICS, For: Mar 31 March 31, 2026 8:01 AM - SEC Filing Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update March 31, 2026 7:30 AM - Globe NewsWire Palvella publishes research on lymphatic malformation subtypes March 30, 2026 7:31 AM - StreetInsider Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations March 30, 2026 7:30 AM - Globe NewsWire Palvella Therapeutics presents research at dermatology meeting March 27, 2026 10:30 AM - StreetInsider Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting March 27, 2026 10:30 AM - Globe NewsWire Palvella Therapeutics (PVLA) PT Raised to $270 at H.C. Wainwright March 24, 2026 10:53 AM - StreetInsider Palvella Therapeutics hires Jennifer McDonough as senior VP March 24, 2026 9:50 AM - StreetInsider Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services March 24, 2026 9:50 AM - Globe NewsWire Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 March 24, 2026 7:30 AM - Globe NewsWire Palvella hires Jennifer McDonough as market access VP March 23, 2026 7:30 AM - StreetInsider Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services March 23, 2026 7:30 AM - Globe NewsWire Form 4 PALVELLA THERAPEUTICS, For: Mar 18 Filed by: Goin Kathleen March 20, 2026 4:05 PM - SEC Filing Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen March 18, 2026 4:01 PM - SEC Filing Clear Street on Palvella Therapeutics (PVLA): 'We view this patent as incrementally positive' March 16, 2026 1:19 PM - StreetInsider Palvella receives European patent for QTORIN rapamycin formulation March 16, 2026 7:31 AM - StreetInsider Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin March 16, 2026 7:30 AM - Globe NewsWire Clear Street Reiterates Buy Rating on Palvella Therapeutics (PVLA) following BEYOND mLM disease-awareness campaign launch March 10, 2026 12:23 PM - StreetInsider Palvella launches disease awareness campaign for rare lymphatic condition March 10, 2026 7:31 AM - StreetInsider Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Or March 10, 2026 7:30 AM - Globe NewsWire Full Article List